Danaparoid sodium

达那类肝素钠

Report date: 2023/06/12 15:15:51
NME

Base Information

Drug NameDanaparoid sodium
Drug Alias Namemucoglucuronan达那肝素钠达那肝素Danaparoid sodowyOrgaran +[8] 
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionAntithrombin-III activatorsFactor Xa inactivationThrombin inactivation
TargetsAntithrombin-IIIProthrombinCoagulation factor X
Therapy Area/IndicationsThrombocytopeniaVenous ThrombosisVenous Thromboembolism
Global Approved IndicationsThrombocytopeniaVenous ThrombosisVenous Thromboembolism
Approved Indications in ChinaN/A
Original Approved Country/TerritoryNetherlands
Original Approved Date1991/01/01
Country/TerritoryBosnia and HerzegovinaCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMerck Sharp & Dohme CorpOrganon
China Registration ClassN/A

Develop Information

Active CompaniesAspen Pharmacare Canada IncLupin Ltd
Inactive CompaniesAspen Global Inc
Active IndicationsThrombocytopeniaVenous Thromboembolism
Inactive IndicationsVenous Thrombosis

Other Information

ATC CodeB01AB09
Related LinksWikipediaDrugBankKEGG